Welcome to our dedicated page for Armata Pharmctcl SEC filings (Ticker: ARMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Armata Pharmaceuticals, Inc. (ARMP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer listed on the NYSE American. Armata files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37544, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports describing material events in its bacteriophage therapeutic programs and corporate activities.
Through these filings, investors can review how Armata reports the progress of its AP-SA02 and AP-PA02 programs, including clinical milestones, regulatory interactions, and funding arrangements. Recent Form 8-K filings have covered topics such as positive Phase 2a diSArm data for AP-SA02 in complicated Staphylococcus aureus bacteremia, an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement to a Phase 3 study, the formal commissioning of the company’s cGMP phage manufacturing facility in Los Angeles, and secured credit agreements with Innoviva Strategic Opportunities LLC.
Filings also detail capital structure and financing tools, including a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC that establishes an at-the-market equity offering program, and secured term loans that are guaranteed by domestic subsidiaries and secured by substantially all of the company’s and certain subsidiaries’ assets. These documents outline key terms, covenants, and potential events of default, giving readers insight into Armata’s financial obligations and liquidity planning.
On Stock Titan, each Armata filing is supplemented with AI-powered summaries that highlight the most important points, helping users quickly understand complex agreements, clinical disclosures, and regulatory language. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks appear promptly, while access to exhibits allows deeper review of credit agreements, sales agreements, and scientific presentations referenced in the filings. For those tracking ARMP, this page offers a focused view of the company’s official regulatory record, including risk disclosures, operating results, and material corporate developments.
Armata Pharmaceuticals announced that the FDA has granted its intravenous S. aureus phage therapy candidate AP-SA02 Qualified Infectious Disease Product (QIDP) status for adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
This QIDP designation provides five additional years of market exclusivity under the GAIN Act and makes AP-SA02 eligible for Fast Track consideration, priority review, and rolling review. Armata plans to request Fast Track designation and advance AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to start in the second half of 2026. Earlier Phase 1b/2a results were positive and development has been partially supported by a $26.2 million Department of Defense award.
Innoviva and its subsidiary report a controlling economic stake in Armata Pharmaceuticals. As of this amendment, they may be deemed to beneficially own 55,467,459 shares of Common Stock, or about 83.1% of Armata’s outstanding Common Stock on an as-converted and as-exercised basis.
This total includes 25,076,769 shares currently outstanding, 10,653,847 shares issuable from warrants, and 19,736,843 shares issuable upon conversion of a secured convertible loan. On January 23, 2026, Armata and Innoviva entities also extended the maturity of several credit agreements to June 1, 2027, pushed the expiration of multiple warrants to January 26, 2031, and updated the expiration terms of a voting agreement to the earlier of January 26, 2031 or U.S. FDA approval of any Armata product candidate.
Armata Pharmaceuticals updated key financing and governance arrangements with its principal shareholder Innoviva. The company amended four existing credit agreements with Innoviva Strategic Opportunities LLC to extend each loan’s maturity date to June 1, 2027, giving Armata more time before repayment is due.
The two parties also amended four existing warrant certificates held by Innoviva Strategic Opportunities LLC, pushing each warrant’s expiration date out to January 26, 2031. These warrants cover specific blocks of common stock, including 1,807,396 shares under a February 9, 2022 warrant and 4,285,935 shares under a March 17, 2021 warrant.
In addition, Armata, Innoviva and Innoviva Strategic Opportunities LLC modified their Second Amended and Restated Voting Agreement so that it now ends on the earlier of January 26, 2031 or approval by the U.S. Food and Drug Administration of any Armata product candidate for marketing and commercial distribution.
Armata Pharmaceuticals reported that it has received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study. The planned trial will focus on patients with complicated S. aureus bacteremia, a serious bloodstream infection.
The company disclosed this update through a press release furnished as an exhibit, emphasizing that the information is being provided for informational purposes and is not deemed filed under securities laws. No financial results or transaction details are included in this report.
Armata Pharmaceuticals, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC to set up an at-the-market stock offering program. Under this arrangement, Armata may, at its discretion, offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000 through JonesTrading as sales agent. Sales can be made on the NYSE American or other permitted markets and in negotiated transactions, with Armata paying JonesTrading a commission of up to 3.0% of gross sale proceeds and reimbursing certain legal expenses. Neither party is obligated to sell or purchase shares, and the program is limited by the amount registered on Armata’s existing Form S-3 shelf registration and the number of authorized but unissued shares.
Armata Pharmaceuticals is launching an at-the-market offering of up to $100,000,000 of common stock through JonesTrading under a Capital on Demand Sales Agreement. JonesTrading will act as sales agent or principal and receive up to 3.0% commission on gross proceeds.
Based on a recent NYSE American price of $7.10 per share, the company illustrates issuance of about 14.1 million shares, which would raise $100.0 million and increase shares outstanding from 36,406,905 to up to 50,491,412. Armata plans to use net proceeds for working capital and general corporate purposes.
The company highlights substantial doubt about its ability to continue as a going concern and a need for significant additional financing, so this program adds flexible access to equity but could cause immediate and substantial dilution. Innoviva, Inc. beneficially owns more than 50% of the common stock, making Armata a controlled company.
Armata Pharmaceuticals (ARMP) filed its Q3 2025 10-Q reporting a net loss of
Cash and cash equivalents were
Financing activity included a
Armata Pharmaceuticals, Inc. filed a current report to note that it has announced its financial results for the three and nine months ended September 30, 2025. The company released these results in a press release dated November 12, 2025, which is attached as Exhibit 99.1.
The company states that the information in this results announcement and the related exhibit is being furnished, not filed, under securities laws, and will not be incorporated by reference into any registration statement or other document under the Securities Act of 1933.
Armata Pharmaceuticals furnished an update on its bacteriophage program. The company announced positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025.
The company furnished a press release as Exhibit 99.1 and posted the late‑breaking oral presentation delivered by Dr. Loren G. Miller on October 22, 2025, furnished as Exhibit 99.2. The materials were provided under Item 7.01 and are not deemed filed under the Exchange Act nor incorporated by reference into Securities Act filings.
Armata Pharmaceuticals filed a Form S-8 to register an additional 1,811,295 shares of common stock for issuance under its 2016 Equity Incentive Plan and 2016 Employee Stock Purchase Plan. The shares break down into 1,809,153 shares added under the Equity Incentive Plan and 2,142 shares under the ESPP pursuant to annual "evergreen" provisions that operate from January 1, 2017 through January 1, 2026. The filing incorporates prior S-8 registration statements and recent SEC filings, including the Annual Report for the year ended December 31, 2024 and quarterly reports for March 31, 2025 and June 30, 2025. The Registration Statement was signed on August 13, 2025 by Chief Executive Officer Deborah L. Birx.